Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ITabMed Ltd.
BeiGene’s $3.5bn Shanghai IPO and CANbridge’s Hong Kong listing, as well as Dizal’s offering on the STAR market and five financing rounds totaling $508.5m help set a record for Chinese biotech fundraising in the last month of 2021.
- Large Molecule
- Other Names / Subsidiaries
- ITabMed Co., Ltd.